PLAQUE PSORIASIS

This completed Phase 3 trial tested the drug guselkumab (Tremfya) in 211 people with skin of color who have moderate-to-severe plaque psoriasis or scalp psoriasis. Participants received either guselkumab or a placebo injection. The study measured how well the drug cleared skin le…

This study is testing how the drug guselkumab affects the immune system in people with two types of psoriasis: plaque and guttate. Twenty-five adults will receive guselkumab injections over 44 weeks. Researchers will measure changes in immune cells in the skin to understand how t…

This study tested a new oral medication, JNJ-77242113, for long-term control of moderate-to-severe plaque psoriasis. 227 adults who completed a previous 16-week study continued treatment for up to 36 more weeks. The goal was to see how well the drug kept skin clear over time.

This study tested an oral tablet called JNJ-77242113 in 90 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to receive the drug or a placebo for 16 weeks. The main goal was to see if the drug could improve psoriasis symptoms by at least 75% com…

This completed Phase 3 trial tested whether the experimental drug zasocitinib works better than the approved drug deucravacitinib for moderate-to-severe plaque psoriasis. Over 600 participants took one tablet and one capsule daily for 16 weeks. The main goal was to see how many a…

This study tested a drug called bimekizumab in 60 adults with moderate-to-severe plaque psoriasis who had not improved with other similar treatments. The drug works by blocking certain inflammatory substances in the body to reduce skin redness, scaling, and thickness. The main go…

This Phase 3 trial tested netakimab, a biologic drug given as a shot, against a placebo in 202 Chinese adults with moderate-to-severe plaque psoriasis. The main goal was to see if netakimab could improve skin symptoms by at least 75% (PASI75) or achieve clear/almost clear skin (s…

This study tested a new daily medicine called ESK-001 in 862 adults with moderate to severe plaque psoriasis. The goal was to see if it reduces psoriasis severity and is safe, comparing it to a placebo and an existing drug (apremilast). Participants took the medicine for 24 weeks…

This study tested whether a new daily pill, ESK-001, can safely reduce psoriasis severity in adults with moderate to severe plaque psoriasis. Over 900 participants took either ESK-001, a placebo (dummy pill), or an approved psoriasis drug (apremilast) for 24 weeks. Researchers me…

This study looked at whether QLETLI, a biosimilar of adalimumab, is safe and effective for children and teens aged 4 to 17 with severe plaque psoriasis. A total of 80 participants were followed for 24 weeks. The main goal was to see how much their psoriasis symptoms improved, mea…

This observational study followed 331 adults with moderate-to-severe plaque psoriasis who were treated with tildrakizumab (Ilumetri) as part of their routine care. Researchers tracked how much the skin cleared and how quality of life improved over up to two years. The goal was to…

This study tested an experimental drug called JNJ-77242113 in 255 adults with moderate-to-severe plaque psoriasis. The goal was to see if different doses could clear at least 75% of skin symptoms after 16 weeks compared to a placebo. Participants had psoriasis for at least 6 mont…

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis who had initially improved on the standard dose of Remicade but later lost that benefit. The goal was to see if the increased dose could again reduce skin symptoms. Participant…

This study tested a gel called SGX302, which is activated by visible light, on 15 people with mild-to-moderate plaque psoriasis. The goal was to see if it could clear or nearly clear skin lesions over 18 weeks. The treatment is applied to the skin and then exposed to light, aimin…

This study tested the drug apremilast (Otezla) in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either apremilast or a placebo pill twice daily for 16 weeks. The main goal was to see if more people on apremilast achieved at least a 75% improvement…

This phase 2 clinical trial tested an experimental oral drug called D-2570 in 161 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to one of three doses of D-2570 or a placebo for 12 weeks. The main goal was to see how many people achieved at l…

This study tested an experimental oral drug called TAK-279 in 1,108 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, a placebo, or an approved psoriasis drug (apremilast) for up to 69 weeks. The main goal was to see if TAK-279 could clear or …

This Phase 3 study tested an experimental oral drug called TAK-279 in 693 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, an approved treatment (apremilast), or a placebo for up to 61 weeks. The main goal was to see if TAK-279 reduces skin p…

This phase 2 trial tested an oral drug called LY3972406 in 33 adults with moderate-to-severe plaque psoriasis. The study compared the drug to a placebo to see if it could reduce skin symptoms. Results will help determine if larger studies are warranted.

This study tested an experimental oral drug called LY4100511 (DC-853) in 222 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to receive different doses of the drug or a placebo. The main goal was to see how well the drug clears skin and whethe…

This study tested whether an artificial intelligence (AI) tool could help primary care doctors diagnose skin conditions more accurately. Nine doctors reviewed 30 images of various skin problems, first giving their own diagnosis and then a final diagnosis after seeing the AI's sug…

This study tests whether a daily skincare routine using Cetaphil cleansers and moisturizers can improve skin symptoms and quality of life for people with mild-to-severe plaque psoriasis. Participants apply the products to one side of their body while continuing their usual prescr…

This study compared a new tapinarof cream to an already-approved one (Vtama®) for treating plaque psoriasis, a skin condition causing red, scaly patches. 575 adults with mild to moderate psoriasis used one of the creams or a placebo for a set time. The goal was to see if the new …

This study involved 324 adults with conditions like Crohn's disease, arthritis, or psoriasis who switched from a standard to a higher-concentration form of adalimumab (AVT-02). Researchers measured injection site pain and how well patients stuck with their treatment over 180 days…

This early-stage study tested a new drug called CAN10, an antibody that blocks a protein involved in inflammation. Researchers gave single doses to 80 healthy adults and repeated doses to people with mild to moderate plaque psoriasis to see if it is safe and how the body processe…

This study tested an experimental drug called TQH3906 in 209 adults with moderate to severe plaque psoriasis. The goal was to see if it could safely clear skin patches and improve symptoms over 12 weeks. Researchers measured how much skin improved using standard psoriasis scores.

This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either AX-158 or a placebo daily for 28 days, then were monitored for another 30 days. The main goal was to see if the drug is safe and tolerable, with some early che…

This study followed 291 adults with mild-to-moderate scalp psoriasis who were prescribed a cream containing calcipotriene and betamethasone (Wynzora®). Researchers measured how satisfied patients were with the treatment, its effect on quality of life, and how well it worked in re…

This study tested whether an artificial intelligence (AI) tool could help doctors diagnose rare and tricky skin conditions like generalized pustular psoriasis (GPP). Fifteen doctors, including both general practitioners and dermatologists, looked at 100 skin images. They first ga…

This study tested whether digital photographs can reliably measure psoriasis severity compared to in-person exams. Thirty-four adults with plaque psoriasis had their skin assessed both ways. The goal was to see if remote scoring could be as accurate as face-to-face evaluation.